KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Aug 27, 2026 >>  ABB India 7495  [ -1.44% ]  ACC 1309.8  [ -1.54% ]  Ambuja Cements 416.2  [ -1.14% ]  Asian Paints 2630  [ 0.00% ]  Axis Bank 1250  [ -0.32% ]  Bajaj Auto 11675  [ -0.64% ]  Bank of Baroda 236.55  [ -2.65% ]  Bharti Airtel 1878  [ -1.42% ]  Bharat Heavy 433  [ 4.27% ]  Bharat Petroleum 319.8  [ 0.49% ]  Britannia Industries 5296.1  [ -0.73% ]  Cipla 1419.9  [ 0.82% ]  Coal India 402  [ -0.46% ]  Colgate Palm 1844.1  [ -1.11% ]  Dabur India 386.35  [ -1.19% ]  DLF 675  [ 0.15% ]  Dr. Reddy's Lab. 1175  [ -0.96% ]  GAIL (India) 173.25  [ -0.83% ]  Grasim Industries 3265  [ -0.66% ]  HCL Technologies 1282.2  [ -1.37% ]  HDFC Bank 712  [ -2.08% ]  Hero MotoCorp 5539.3  [ -1.26% ]  Hindustan Unilever 2007  [ -1.13% ]  Hindalco Industries 1024  [ -3.21% ]  ICICI Bank 1444  [ 0.93% ]  Indian Hotels Co. 720  [ -0.41% ]  IndusInd Bank 970  [ -3.19% ]  Infosys 1106.65  [ -1.26% ]  ITC 267.4  [ -1.27% ]  Jindal Steel 1166.8  [ -0.80% ]  Kotak Mahindra Bank 423.3  [ 1.71% ]  L&T 4033.1  [ -0.26% ]  Lupin 2164.6  [ -1.21% ]  Mahi. & Mahi 3338  [ -1.77% ]  Maruti Suzuki India 13428  [ -0.74% ]  MTNL 26.55  [ -1.04% ]  Nestle India 1449.5  [ -0.10% ]  NIIT 102.96  [ -0.03% ]  NMDC 86  [ -2.71% ]  NTPC 328.7  [ -2.03% ]  ONGC 232  [ -0.39% ]  Punj. NationlBak 112  [ -3.32% ]  Power Grid Corpn. 264.85  [ -0.43% ]  Reliance Industries 1286  [ -1.00% ]  SBI 1044.9  [ -0.84% ]  Vedanta 281  [ -1.97% ]  Shipping Corpn. 292.55  [ 1.39% ]  Sun Pharmaceutical 1900.5  [ -0.03% ]  Tata Chemicals 644.1  [ 1.55% ]  Tata Consumer 1041.9  [ -0.51% ]  Tata Motors Passenge 316.15  [ 0.68% ]  Tata Steel 186.4  [ -1.09% ]  Tata Power Co. 352  [ -3.65% ]  Tata Consult. Serv. 2252  [ -0.84% ]  Tech Mahindra 1585.6  [ 0.80% ]  UltraTech Cement 11717.85  [ -0.28% ]  United Spirits 1521.8  [ -0.42% ]  Wipro 177  [ -0.23% ]  Zee Entertainment 104.05  [ -0.34% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

MANKIND PHARMA LTD.

27 August 2026 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE634S01028 BSE Code / NSE Code 543904 / MANKIND Book Value (Rs.) 408.49 Face Value 1.00
Bookclosure 08/08/2025 52Week High 2674 EPS 46.32 P/E 52.19
Market Cap. 99841.78 Cr. 52Week Low 1910 P/BV / Div Yield (%) 5.92 / 0.04 Market Lot 1.00
Security Type Other

History of Company

The company history sections lists out major chronological events that happened to the company.
The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.

Major events and milestones:

2004 
-Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others

2005 
-Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh
-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others

2007 
-Entered the consumer healthcare segment with the launch of `Manforce' brand
-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised Rs.720 million from Monet Limited

2009 
-Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh

2010 
-Launched `Preganews' brand in the consumer healthcare segment

2012 
-Setup the first R&D centre at IMT Manesar, Haryana

2014 
-Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)
-Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh

2015 
-Incorporated the Subsidiary, Lifestar Pharma LLC in the US
-Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore

2017 
-Set up the manufacturing facility in Sikkim

2018 
-The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time

2019 
-Entered the female infertility segment with the launch of `Dydroboon' tablets

2020 
-Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal
-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets
-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets

2021 
-Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE
-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets
-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets

2022 
-Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited
-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others
-Entered into oncology segment with the launch of `Pacliall' injection amongst others
-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories
-The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.

2023
-Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.
-Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.
-Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.

2024
-Mankind Pharma Completes Landmark Acquisition of BSV.
-Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.
-Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.
-Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).

2025
-The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited  and Jaspack Industries Private Limited  with Mankind Pharma Limited